OLMA vs ONCY

Olema Pharmaceuticals, Inc. vs Oncolytics Biotech Inc. — Valuation Comparison 2026

OLMA

Pharmaceutical Preparations
Olema Pharmaceuticals, Inc.
Quality
5.0
out of 10
Value Trap
18
SAFE
Price
$13.19
Last close
Models
7/13
Active
VS

ONCY

Pharmaceutical Preparations
Oncolytics Biotech Inc.
Quality
3.4
out of 10
Value Trap
Price
$1.04
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType OLMA Fair ValueOLMA Upside ONCY Fair ValueONCY Upside
Bayesian DCF Intrinsic $4.00 -69.7% $0.24 -77.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.71 -64.3% $0.16 -84.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OLMA vs ONCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OLMA vs ONCY — Which Stock Is More Undervalued?

OLMA scores higher with a 5.0/10 quality rating vs ONCY's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Olema Pharmaceuticals, Inc. (OLMA) and Oncolytics Biotech Inc. (ONCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OLMA currently trades at $13.19 with a QOC of 5.0/10, while ONCY trades at $1.04 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).